Table 1 Clinical characteristics of non-septic patients and sepsis patients
From: miPEP31 alleviates sepsis development by regulating Chi3l1-dependent macrophage polarization
|  | Control group (n = 5) | Sepsis group (survivors, n = 5) | Sepsis group (non-survivors, n = 5) |
|---|---|---|---|
Age, mean (SEM) | 59.6(5.9) | 72(3.3) | 75(4.4) |
Gender n% | Â | Â | Â |
Male | 3(60%) | 4(80%) | 3(60%) |
Female | 2(40%) | 1(20%) | 2(40%) |
APACHE II, mean (SEM) | N/A | 19.4(2.4) | 32.2(4.3) |
SOFA, mean (SEM) | N/A | 6.8(1.4) | 13.8(2.3) |
GCS, mean (SEM) | N/A | 11.2(1.3) | 4.8(1.1) |
Procalcitonin, mean (SEM) | N/A | 3.2(1.8) | 3.4(2.0) |
CRP, mean (SEM) | N/A | 128.6(44.7) | 141.9(20.7) |
WBC, mean (SEM) | N/A | 11.7(2.1) | 7.9(3.1) |
IL-6, mean (SEM) | N/A | 47.6(23.0) | 1089.7(735.3) |
ICU stay, days, median (range) | N/A | 21(15–55) | 24(21–28) |